Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 2Stomach Neoplasms 1Solid Tumors 1Solid Tumor, Adult 1Salivary Gland Neoplasms 1RAS/BRAF Wild-type Advanced Colorectal Cancer Patients 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Non-small Cell Lung Cancers 1Lung Neoplasms 1Locally Recurrent Skin Squamous Cell Carcinoma 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × amivantamab × Clear all
NCT05117931 2026-02-17

A Study of Amivantamab in People With Esophagogastric Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
25 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡